Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BID | P55957 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737076 | 1.00 | GHSR (0.68) | GHSROPRM1ACEKMT2ABCL2A1 | |
| SCHEMBL736961 | 1.00 | GHSR (0.68) | GHSROPRM1ACEKMT2ABCL2A1 | |
| SCHEMBL736964 | 0.94 | GHSR (0.69) | GHSROPRM1ACE | |
| SCHEMBL736840 | 0.93 | GHSR (0.68) | GHSROPRM1ACEKMT2A | |
| SCHEMBL736965 | 0.92 | GHSR (0.66) | GHSROPRM1ACE | |
| SCHEMBL737818 | 0.91 | GHSR (0.52) | GHSROPRM1SMN1; SMN2TACR1 | |
| SCHEMBL737045 | 0.91 | GHSR (0.65) | GHSROPRM1ACEKMT2A | |
| SCHEMBL736951 | 0.90 | GHSR (0.85) | GHSROPRM1ACE | |
| SCHEMBL737019 | 0.90 | GHSR (0.85) | GHSROPRM1ACE | |
| SCHEMBL738184 | 0.89 | GHSR (0.65) | GHSROPRM1ACEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138218-B2 | Growth hormone secretagogues | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| US-20090131478-A1 | Growth Hormone Secretagogues | IPSEN PHARMA S.A.S. (FR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131478-A1 | Growth Hormone Secretagogues | GHSR, GHRHR, GHITM | GHSR 1/4885OPRM1 3398/4885ACE 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.